Ticker > Company >

Senores Pharmaceutic share price

Senores Pharmaceuticals Ltd.

NSE: SENORES BSE: 544319 SECTOR: Pharmaceuticals & Drugs  14.66 K   15   2

686.75
-2.10 (-0.30%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 699.95

Today's Low

₹ 681

52 Week High

₹ 750.65

52 Week Low

₹ 440

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

3162.73 Cr.

Enterprise Value

2896.98 Cr.

No. of Shares

4.61 Cr.

P/E

857.15

P/B

4.45

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  154.31

CASH

359.72 Cr.

DEBT

93.97 Cr.

Promoter Holding

45.78 %

EPS (TTM)

₹  0.8

Sales Growth

13.32%

ROE

0.84 %

ROCE

2.19%

Profit Growth

355.56 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year13.32%
3 Year41.7%
5 YearNA

Profit Growth

1 Year355.56%
3 Year75.57%
5 YearNA

ROE%

1 Year0.84%
3 Year1.64%

ROCE %

1 Year2.19%
3 Year3.45%

Debt/Equity

0.1327

Price to Cash Flow

-155.04

Interest Cover Ratio

1.7837

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 45.78 0.00
Mar 2025 45.77 0.00
Dec 2024 45.76 0.00
Sep 2024 45.76 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 75.5724851495877% for the Past 3 years.
  • The company has shown a good revenue growth of 41.7030700558477% for the Past 3 years.
  • The company has an efficient Cash Conversion Cycle of 35.1621 days.
  • Company has a healthy liquidity position with current ratio of 9.9947.

 Limitations

  • Company has a poor ROE of 1.6424% over the past 3 years.
  • Company has a poor ROCE of 3.45426666666667% over the past 3 years
  • Company has high debtor days of 225.8757.
  • Company has contingent liabilities of 152.95 Cr.
  • Company has negative cash flow from operations of -20.4.
  • The company has a low EBITDA margin of 0% over the past 5 years.
  • The company is trading at a high PE of 857.15.
  • The company is trading at a high EV/EBITDA of 196.9395.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2024 Mar 2025 Jun 2025
Net Sales 9.59 11.86 19.82
Total Expenditure 12.01 14.59 20.98
Operating Profit -2.42 -2.73 -1.16
Other Income 7.19 9.25 8.39
Interest 2.7 2.35 1.76
Depreciation 0.75 1.27 1.88
Exceptional Items 0 0 0
Profit Before Tax 1.32 2.9 3.59
Tax 0.25 0.89 0.89
Profit After Tax 1.07 2.01 2.7
Adjusted EPS (Rs) 0.23 0.44 0.59

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 13.54 12.38 34.01 38.54
Total Expenditure 12.39 14.16 34.08 45.89
Operating Profit 1.16 -1.78 -0.07 -7.35
Other Income 0.94 6.79 6.85 22.06
Interest 0.56 2.14 2.71 6.52
Depreciation 0.71 0.93 2.04 3.08
Exceptional Items 0 0 0 0
Profit Before Tax 0.83 1.94 2.03 5.11
Tax 0.15 0.74 1.22 1.42
Net Profit 0.68 1.2 0.81 3.69
Adjusted EPS (Rs.) 0.78 1.22 0.27 0.8

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 8.74 9.82 30.51 46.05
Total Reserves 24.95 29.11 137.61 661.91
Borrowings 12.22 24.17 19.88 76.26
Other N/C liabilities 0.01 1.66 7.01 8.34
Current liabilities 8.8 46.79 90.66 41.23
Total Liabilities 54.72 111.54 285.67 833.79
Assets
Net Block 1.59 7.77 24.09 54.59
Capital WIP 0 8.06 14.88 34.01
Intangible WIP 3.17 3.27 3.59 0
Investments 11.69 8.23 81.58 104.37
Loans & Advances 24.14 56.13 102.08 225.83
Other N/C Assets 0.14 0.4 19.48 2.91
Current Assets 13.98 27.68 39.97 412.08
Total Assets 54.72 111.54 285.67 833.79
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 0.83 1.94 2.03 5.11
Adjustment 0.6 -1.57 -2.58 -9.9
Changes in Assets & Liabilities -25.35 -43.32 -17.51 -14.16
Tax Paid -0.14 -0.47 -1.2 -1.45
Operating Cash Flow -24.06 -43.41 -19.26 -20.4
Investing Cash Flow -10.05 -5.23 -57.07 -162.94
Financing Cash Flow 33.88 47.08 86.68 532.62
Net Cash Flow -0.23 -1.57 10.35 349.28

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 45.76 45.76 45.77 45.78
anar swapnil shah 4.98 4.98 4.98 4.98
ashokbhai vijaysinh barot... 7.44 7.44 7.44 7.44
aviraj group llc 1.49 1.49 1.49 1.49
aviraj overseas llc 4.12 4.12 4.12 4.12
dhananjay ashokkumar baro... 0.72 0.72 0.72 0.72
espee therapeutics llp 1.07 1.07 1.07 1.07
hemant ishwarlal modi 0.13 0.13 0.13 0.13
jatin siddharthbhai shah - 0.07 0.07 0.07
jitendra babulal sanghvi 1.06 1.06 1.06 1.06
mukur yogeshkumar barot 0.99 0.99 0.99 0.99
pinky jatin shah 0.07 0.07 0.07 0.07
remus pharmaceuticals lim... 7.08 7.08 7.08 7.08
renosen pharmaceuticals p... 5.85 5.85 5.86 5.87
sangeeta mukur barot 2.26 2.26 2.26 2.26
shantaben babulal sanghvi... 0.71 0.71 0.71 0.71
swapnil jatin shah 7.72 7.72 7.72 7.72
jaitn siddharth shah 0.07 - - -
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 54.24 54.24 54.23 54.22
aditya birla sun life ins... - 2.81 3.71 4.05
astorne capital vcc - arv... - - 1.83 2.16
icici prudential pharma h... - - 1.39 1.39
jayanti mishrimal sanghvi... 1.45 1.45 1.45 1.45
jigar prakash sanghvi 1.19 1.19 1.19 1.19
llp 0.14 - 0.26 0.40
mahindra manulife large &... 1.11 1.11 1.11 1.11
manoj prakash sanghvi 1.88 1.88 1.88 1.88
prakash mishrimal sanghvi... - 1.03 1.03 1.03
ratnamani marketing priva... 1.82 1.82 1.82 1.82
sanghavi pavankumar mishr... 1.10 1.10 1.10 1.10
bank of india mid & small... - 1.11 - -
icici prudential equity s... 2.94 2.78 - -
aditya birla sun life ins... 2.81 - - -
bank of india multi cap f... 1.11 - - -
prakash misrimal sanghvi 1.03 - - -

Annual Reports

Title Link
Title Link
Annual Report 2025

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY25
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY25
Presentation Q3FY25

Company News

Senores Pharmaceuticals signs agreement to acquire ANDAs from Teva Pharmaceuticals USA, Inc 13 Aug, 10:47 AM Senores Pharmaceuticals informs about disclosure 30 Jul, 12:39 PM Senores Pharmaceuticals informs about disclosure 30 Jul, 12:38 PM Senores Pharmaceuticals informs about updates 28 Jul, 5:01 PM Senores Pharmaceutic - Quaterly Results 23 Jul, 6:49 PM Senores Pharmaceutic - Quaterly Results 23 Jul, 6:49 PM Senores Pharmaceutic - Quaterly Results 23 Jul, 6:49 PM Senores Pharmaceuticals informs about earnings conference call 19 Jul, 2:48 PM Senores Pharmaceuticals to acquire 2.97% stake in Havix 11 Jul, 12:12 PM Senores Pharmaceuticals informs about updates 23 Jun, 2:28 PM Senores Pharmaceuticals informs about outcome of board meeting 2 Jun, 5:21 PM Senores Pharmaceuticals inks pact to acquire ANDA for Enalapril Maleate Tablets 21 May, 10:22 AM Senores Pharmaceutic - Quaterly Results 15 May, 7:08 PM Senores Pharmaceutic - Quaterly Results 15 May, 7:08 PM Senores Pharmaceuticals informs about media release 9 May, 12:51 PM Senores Pharmaceuticals informs about media release 9 May, 9:58 AM Senores Pharmaceuticals inks agreement to acquire ANDA for Tramadol Tablets 9 May, 9:22 AM Senores Pharmaceuticals inks agreement to acquire ANDA for Topiramate HCl 25, 50, 100, 200 mg tablets 5 May, 6:02 PM Senores Pharmaceuticals informs about updates 22 Apr, 5:01 PM Senores Pharmaceuticals informs about change in contact details of RTA 19 Apr, 4:24 PM Senores Pharmaceuticals informs about certificate 3 Apr, 5:24 PM Senores Pharmaceuticals to acquire 3.73% paid up share capital of Havix 12 Mar, 12:23 PM Senores Pharmaceuticals acquires 14 ANDAs from Dr. Reddy’s Laboratories 4 Mar, 3:58 PM Senores Pharmaceuticals starts operations at greenfield API facility in Gujarat 27 Feb, 9:44 AM Senores Pharmaceuticals inks pact to acquire ANDA for Roflumilast 250 mcg, 500 mcg tablets 21 Feb, 10:38 AM Senores Pharmaceuticals informs about press release 24 Jan, 3:25 PM Senores Pharmaceuticals informs about media release 23 Jan, 5:25 PM Senores Pharmaceutic - Quaterly Results 23 Jan, 1:55 PM Senores Pharmaceutic - Quaterly Results 23 Jan, 1:55 PM Senores Pharmaceutic - Quaterly Results 23 Jan, 1:55 PM Senores gets USFDA’s final nod for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet 10 Jan, 9:22 AM Senores Pharmaceuticals coming with IPO to raise upto Rs 608 crore 19 Dec, 4:08 PM Senores Pharmaceuticals gets Sebi's nod to float IPO 16 Oct, 12:22 PM

Senores Pharmaceutic Stock Price Analysis and Quick Research Report. Is Senores Pharmaceutic an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Senores Pharmaceutic. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Senores Pharmaceutic has a PE ratio of 853.532201697454 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Senores Pharmaceutic has ROA of 0.6592% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Senores Pharmaceutic has a Current ratio of 9.9947.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Senores Pharmaceutic has a ROE of 0.8424%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Senores Pharmaceutic has a Debt to Equity ratio of 0.1327 which means that the company has low proportion of debt in its capital.

  • Sales growth: Senores Pharmaceutic has reported revenue growth of 13.3196% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Senores Pharmaceutic for the current financial year is -19.0710949662688%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Senores Pharmaceutic is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Senores Pharmaceutic is Rs 0.8012. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Senores Pharmaceutic in Ticker for free. Also, one can get the intrinsic value of Senores Pharmaceutic by using Valuation Calculators, which are available with a Finology ONE subscription. 

Senores Pharmaceutic FAQs

Q1. What is Senores Pharmaceutic share price today?
Ans: The current share price of Senores Pharmaceutic is Rs 683.85.

Q2. What is the market capitalisation of Senores Pharmaceutic?
Ans: Senores Pharmaceutic has a market capitalisation of Rs 3149.37461538 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Senores Pharmaceutic?
Ans: The PE ratio of Senores Pharmaceutic is 853.532201697454 and the P/B ratio of Senores Pharmaceutic is 4.4315974812118, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Senores Pharmaceutic share?
Ans: The 52-week high share price of Senores Pharmaceutic is Rs 751.2, and the 52-week low share price of Senores Pharmaceutic is Rs 435.25.

Q5. Does Senores Pharmaceutic pay dividends?
Ans: Currently, Senores Pharmaceutic does not pay dividends. Dividend yield of Senores Pharmaceutic is around 0%.

Q6. What are the face value and book value of Senores Pharmaceutic shares?
Ans: The face value of Senores Pharmaceutic shares is Rs 10, while the book value per share of Senores Pharmaceutic is around Rs 154.3123. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Senores Pharmaceutic?
Ans: Senores Pharmaceutic has a total debt of Rs 93.97 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Senores Pharmaceutic?
Ans: The ROE of Senores Pharmaceutic is 0.8424% and ROCE of Senores Pharmaceutic is 2.1885%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Senores Pharmaceutic a good buy for the long term?
Ans: The Senores Pharmaceutic long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Senores Pharmaceutic undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Senores Pharmaceutic appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Senores Pharmaceutic’s financials?
Ans: You can review Senores Pharmaceutic’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Senores Pharmaceutic
X